title: Pamidronate attenuates diastolic dysfunction induced by myocardial infarction associated with changes in geometric patterning.
abstract: OBJECTIVE
  The aim of this study was to evaluate the influence of pamidronate on ventricular remodeling after myocardial infarction.
  
  
  METHODS
  Male Wistar rats were assigned to four groups: a sham group, in which animals were submitted to simulated surgery and received weekly subcutaneous injection of saline (S group; n=14); a group in which animals received weekly subcutaneous injection of pamidronate (3 mg/kg of body weight) and were submitted to simulated surgery (SP group, n=14); a myocardial infarction group, in which animals were submitted to coronary artery ligation and received weekly subcutaneous injection of saline (MI group, n=13); and a myocardial infarction group with pamidronate treatment (MIP group, n=14). The rats were observed for three months.
  
  
  RESULTS
  Animals submitted to MI had left chamber enlargement and worse diastolic and systolic function compared with SHAM groups. E/A ratio, LV posterior and relative wall thickness were lower in the MIP compared with the MI group. There was no interaction between pamidronate administration and MI on systolic function, myocyte hypertrophy, collagen content, and calcium handling proteins.
  
  
  CONCLUSIONS
  Pamidronate attenuates diastolic dysfunction following MI.
authors.affiliation: Internal Medicine Department, Botucatu Medical School, Univ Estadual Paulista (UNESP), Botucatu, Brazil.
authors.forename: Andréa F
authors.initials: AF
authors.lastname: Gonçalves
authors.forename: Luiz Henrique
authors.initials: LH
authors.lastname: Congio
authors.forename: Priscila P
authors.initials: PP
authors.lastname: dos Santos
authors.forename: Bruna P M
authors.initials: BP
authors.lastname: Rafacho
authors.forename: Bruna L B
authors.initials: BL
authors.lastname: Pereira
authors.forename: Renan F T
authors.initials: RF
authors.lastname: Claro
authors.forename: Nara A
authors.initials: NA
authors.lastname: Costa
authors.forename: Fernanda
authors.initials: F
authors.lastname: Chiuso-Minicucci
authors.forename: Paula S
authors.initials: PS
authors.lastname: Azevedo
authors.forename: Bertha F
authors.initials: BF
authors.lastname: Polegato
authors.forename: Katashi
authors.initials: K
authors.lastname: Okoshi
authors.forename: Elenize J
authors.initials: EJ
authors.lastname: Pereira
authors.forename: Marina P
authors.initials: MP
authors.lastname: Okoshi
authors.forename: Sergio A R
authors.initials: SA
authors.lastname: Paiva
authors.forename: Leonardo A M
authors.initials: LA
authors.lastname: Zornoff
authors.forename: Marcos F
authors.initials: MF
authors.lastname: Minicucci
mesh_terms: D000818:Animals; D015815:Cell Adhesion Molecules / Q000378:metabolism; D004164:Diphosphonates / Q000494:pharmacology* / Q000627:therapeutic use; D004452:Echocardiography; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D009203:Myocardial Infarction / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D000077268:Pamidronate; D051381:Rats; D017208:Rats, Wistar; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases / Q000378:metabolism; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000378:metabolism; D020257:Ventricular Remodeling / Q000187:drug effects*
chemical_list: C506948:Atp2a2 protein, rat; D015815:Cell Adhesion Molecules; D004164:Diphosphonates; C512836:Postn protein, rat; D019715:Tissue Inhibitor of Metalloproteinase-1; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases; D000077268:Pamidronate